Discovery of torezolid as a novel 5-hydroxymethyl-oxazolidinone antibacterial agent

European Journal of Medicinal Chemistry

Volumn 46, Issue 4, 2011, Pages 1027-1039

  Im, Weon Bin ^a,b   Choi, Sun Ho ^b   Park, Ju Young ^a   Choi, Sung Hak ^b   Finn, John ^c   Yoon, Sung Hwa ^a  

^a Ajou University   (South Korea)

^b Dong A Pharmaceutical Company   (South Korea)

^c Trius Therapeutics Inc   (United States)

Author keywords

Antibacterial activity; Antibiotics; DA 7867; Oxazolidinone; Prodrug; Pyridine

Indexed keywords

2 (BENZYL) N [[3 [3 FLUORO 4 [6 (2 METHYL 2H TETRAZOL 5 YL)PYRIDIN 3 YL]PHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL]ACETAMIDE; 3 [4 [2 (2 METHYL[1,3,4]OXADIAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 ([1,2,3] TRIAZOL 1 YL)METHYLOXAZOLIDIN 2 ONE; 3 [4 [2 (2 METHYL[1,3,4]OXADIAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 (ISOXAZOL 3 YL OXY)METHYLOXAZOLIDIN 2 ONE; 3 [4 [2 (2 METHYL[1,3,4]OXADIAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 HYDROXYMETHYLOXAZOLIDIN 2 ONE; 3 [4 [2 (2 METHYL[1,3,4]OXADIAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 METHANESULFONYLOXYMETHYLOXAZOLIDIN 2 ONE; 3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 ([1,2,3] TRIAZOL 1 YL)METHYLOXAZOLIDIN 2 ONE; 3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 ([1,2,3] TRIAZOL 2 YL)METHYLOXAZOLIDIN 2 ONE; 3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 ([1,2,4] TRIAZOL 1 YL)METHYLOXAZOLIDIN 2 ONE; 3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 (ALANYLOXY)METHYLOXAZOLIDIN 2 ONE; 3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 (ALANYLOXY)METHYLOXAZOLIDIN 2 ONE TRIFLUOROACETIC ACID; 3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 (BETA ALANYLOXY)METHYLOXAZOLIDIN 2 ONE; 3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 (BETA ALANYLOXY)METHYLOXAZOLIDIN 2 ONE TRIFLUOROACETIC ACID; 3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 (ISOXAZOL 3 YL OXY)METHYLOXAZOLIDIN 2 ONE; 3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 (N,N DIMETHYLAMINOMETHYL)OXAZOLIDIN 2 ONE; 3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 (PROLINYLOXY)METHYLOXAZOLIDIN 2 ONE TRIFLUOROACETIC ACID; 3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 (VALYLOXY)METHYLOXAZOLIDIN 2 ONE; 3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 (VALYLOXY)METHYLOXAZOLIDIN 2 ONE TRIFLUOROACETIC ACID; 3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 FLUOROMETHYLOXAZOLIDIN 2 ONE; 3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 GLYCYLOXYMETHYLOXAZOLIDIN 2 ONE; 3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 GLYCYLOXYMETHYLOXAZOLIDIN 2 ONE TRIFLUOROACETIC ACID; 3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 HYDROXYMETHYLOXAZOLIDIN 2 ONE; 3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 METHOXYMETHYLOXAZOLIDIN 2 ONE; 3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 5 N METHYLAMINOMETHYLOXAZOLIDIN 2 ONE; LINEZOLID; N [[3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL] 2 HYDROXYACETAMIDE; N [[3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL] 2 METHOXYACETAMIDE; N [[3 [4 [2 (2 METHYLTETRAZOL 5 YL)PYRIDIN 5 YL] 3 FLUOROPHENYL] 2 OXOOXAZOLIDIN 5 YL]METHYL]FURAN 2 CARBOXAMIDE; OXAZOLIDINONE DERIVATIVE; TOREZOLID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; HAEMOPHILUS INFLUENZAE; HALF LIFE TIME; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; STAPHYLOCOCCUS INFECTION; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; DRUG DISCOVERY; MALE; MICE; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; OXAZOLIDINONES; PRODRUGS; SOLUBILITY; TETRAZOLES;

EID: 79952280648     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.01.014     Document Type: Article

References (27)

1. H.W. Boucher, G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert, L.B. Rice, M. Scheld, B. Spellberg, and J. Bartlett Clin. Infect. Dis. 48 2009 1 12
2. R.C. Moellering Jr. Clin. Infect. Dis. 46 2008 1032 1037
3. R. Wenzel, and M. Edmond Emerg. Infect. Dis. 7 2001 174 177
4. G. Steinkraus, R. White, and L. Freidrich J. Antimicrob. Chemother. 60 2007 788 794
5. M.R. Barbachyn, and C.W. Ford Angew. Chem. Int. Ed. 42 2003 2010 2023
6. D.L. Stevens, L.G. Smith, J.B. Bruss, M.A. McConnell-Martin, S.E. Duvall, W.M. Todd, and B. Hafkin Antimicrob. Agents Chemother. 44 2000 3408 3413
7. Y. Jo, W. Im, J. Rhee, M. Shim, W. Kim, and E. Choi Bioorg. Med. Chem. 12 2004 5909 5915
8. E.J. Yoon, Y.W. Jo, S.H. Choi, T.H. Lee, J.K. Rhee, M. Yoo, M.J. Shim, and E.C. Choi Antimicrob. Agents Chemother. 49 2005 2498 2500
9. F. Reck, F. Zhou, C.J. Eyermann, G. Kern, D. Carcanague, G. Ioannidis, R. Illingworth, G. Poon, and M.B. Gravestock J. Med. Chem. 50 2007 4868 4881
10. F.E. Boyer, J.V.N.V. Prasad, A.L. Choy, L. Chupak, M.R. Dermyer, Q. Ding, M.D. Huband, W. Jiao, T. Kaneko, V. Khlebnikov, J.Y. Kim, M.S. Lall, S.N. Maiti, K. Romero, and X. Wu Bioorg. Med. Chem. Lett. 17 2007 4694 4698
11. T. Komine, A. Kojima, Y. Asahina, T. Saito, H. Takano, T. Shibue, and Y. Fukuda J. Med. Chem. 51 2008 6558 6562
12. E. Skripkin, T.S. McConnell, J. DeVito, L. Lawrence, J.A. Ippolito, E.M. Duffy, J. Sutcliffe, and F. Franceschi Antimicrob. Agents Chemother. 52 2008 3550 3557
13. J. Zhou, A. Bhattacharjee, S. Chen, Y. Chen, E. Duffy, J. Farmer, J. Goldberg, R. Hanselmann, J.A. Ippolito, R. Lou, A. Orbin, A. Oyelere, J. Salvino, D. Springer, J. Tran, D. Wang, Y. Wu, and G. Johnson Bioorg. Med. Chem. Lett. 18 2008 6175 6178
14. J. Zhou, A. Bhattacharjee, S. Chen, Y. Chen, E. Duffy, J. Farmer, J. Goldberg, R. Hanselmann, J.A. Ippolito, R. Lou, A. Orbin, A. Oyelere, J. Salvino, D. Springer, J. Tran, D. Wang, J. Wu, and G. Johnson Bioorg. Med. Chem. Lett. 18 2008 6179 6183
15. P. Manninen, and S. Brickner Org. Synth. 81 2004 112 120
16. M.B. Gravestock, D.G. Acton, M.J. Betts, M. Dennis, G. Hatter, A. McGregor, M.L. Swain, R.G. Wilson, L. Woods, and A. Wookey Bioorg. Med. Chem. Lett. 13 2003 4179 4186
17. J.V.N.V. Prasad Curr. Opin. Microbiol. 10 2007 454 460
18. W.A. Gregory, D.R. Brittelli, C.L.J. Wang, M.A. Wuonola, R.J. McRipley, D.C. Eustice, V.S. Eberly, A.M. Slee, M. Forbes, and P.T. Bartholomew J. Med. Chem. 32 1989 1673 1681
19. S. Bae, W.S. Chung, E.J. Kim, J.K. Rhee, J.W. Kwon, W.B. Kim, and M.G. Lee Antimicrob. Agents Chemother. 48 2004 659 662
20. S.J. Brickner Curr. Pharm. Des. 2 1996 175 194
21. J.S. Daly, G.M. Eliopoulos, S. Willey, and R.C. Moellering Antimicrob. Agents Chemother. 32 1988 1341 1346
22. K.L. Leach, S.M. Swaney, J.R. Colca, W.G. McDonald, J.R. Blinn, L.M. Thomasco, R.C. Gadwood, D. Shinabarger, L. Xiong, and A.S. Mankin Mol. Cell 26 2007 393 402
23. J.A. Ippolito, Z.F. Kanyo, D. Wang, F.J. Franceschi, P.B. Moore, T.A. Steitz, and E.M. Duffy J. Med. Chem. 51 2008 3353 3356
24. D.N. Wilson, F.S. Schluenzen, J.M. Harms, A.L. Starosta, S.R. Connell, and P. Fucini Proc. Natl. Acad. Sci. U.S.A. 105 2008 13339 13344
25. K.J. Shaw, S. Poppe, R. Schaadt, V. Brown-Driver, J. Finn, C.M. Pillar, D. Shinabarger, and G. Zurenko Antimicrob. Agents Chemother. 52 2008 4442 4447
26. P. Bien, K. Munoz, J. Bohn, R. Wright, C. Bethune, P. Prokocimer, Abstracts to the 48th Annual ICCAC Meeting, 2008, pp. F1-2063.
27. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing, 20th Informational Supplement 2010 Clinical and Laboratory Standards Institute Wayne, PA pp. M100-S20